Publications by authors named "Suzanne de Bruyn"
Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants, the elderly, and immune-compromised patients. While a half-life extended monoclonal antibody and 2 vaccines have recently been approved for infants and the elderly, respectively, options to prevent disease in immune-compromised patients are still needed. Here, we describe spiro-azetidine oxindoles as small molecule RSV entry inhibitors displaying favorable potency, developability attributes, and long-acting PK when injected as an aqueous suspension, suggesting their potential to prevent complications following RSV infection over a period of 3 to 6 months with 1 or 2 long-acting intramuscular (IM) or subcutaneous (SC) injections in these immune-compromised patients.
View Article and Find Full Text PDFRespiratory syncytial virus (RSV) can cause pulmonary complications in infants, elderly and immunocompromised patients. While two vaccines and two prophylactic monoclonal antibodies are now available, treatment options are still needed. JNJ-7184 is a non-nucleoside inhibitor of the RSV-Large (L) polymerase, displaying potent inhibition of both RSV-A and -B strains.
View Article and Find Full Text PDFArticle Synopsis
- - The respiratory syncytial virus (RSV) polymerase complex, made up of proteins L and P, is essential for RNA transcription and modification, but details on how inhibitors interact with it have been unclear.
- - A new non-nucleoside inhibitor, JNJ-8003, demonstrates strong antiviral activity and effectively inhibits the polymerase complex, with structural analysis showing how it tightly binds to a specific site on the capping domain.
- - JNJ-8003 disrupts early stages of RNA synthesis, revealing potential for developing broad-spectrum antiviral treatments based on its molecular interactions with the viral polymerase machinery.